SCHEMBL302045

SCHEMBL302045

Cn1cnc(S(=O)(=O)N(Cc2ccccc2)c2ccc(C(=O)N3CCN(c4nccs4)CC3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.53
LMNA P02545 3/20 0.51
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 2/20 0.47
GAA P10253 2/20 0.46
MEN1 O00255 1/20 0.45
FNTA P49354 6/20 0.43
FNTB P49356 6/20 0.43
SCD O00767 1/20 0.41
PGGT1B P53609 4/20 0.41
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
ALDH1A1 P00352 1/20 0.39
OXTR P30559 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303692 0.88 LMNA (0.66) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL1722406 0.87 LMNA (0.58) SLC6A7LMNAHTTSMN1; SMN2KMT2A
SCHEMBL3275527 0.84 LMNA (0.51) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL1723243 0.83 LMNA (0.54) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL1725046 0.82 LMNA (0.54) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL303115 0.82 LMNA (0.52) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL3274787 0.81 LMNA (0.52) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL1725647 0.80 LMNA (0.53) LMNAHTTSMN1; SMN2KMT2AGAA
SCHEMBL302272 0.80 KMT2A (0.51) LMNAHTTSMN1; SMN2KMT2AHPGD
SCHEMBL302686 0.79 LMNA (0.49) LMNAHTTSMN1; SMN2KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 SLC6A7 581/4885LMNA 1683/4885HTT 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.